FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI

FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU

FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Tokyo , Japan , Haruo Naito , University College London , Prnewswire Eisai Co Ltd , National Institutes Of Health , Eisai Inc , National Institute On , Drug Administration , Eisai Co Ltd Investor Relations Department , Alzheimer Network , Washington University School Of Medicine , Eisai Inc Us Libby , Eisai Co Ltd , Alzheimer Network Trials Unit , Public Relations Department , Alzheimer Clinical Trial Consortium , Washington University School , Tau Nexgen , Ltd Investor Relations , Dominantly Inherited Alzheimer Network , Inherited Alzheimer , University College , Clinical Trial Consortium , National Institute , National Institutes , Biologics License Application , Breakthrough Therapy , Disease Assessment Scale Cognitive , Clinical Dementia Rating , Mini Mental State Examination ,